Premium
Cervimycin A–D: A Polyketide Glycoside Complex from a Cave Bacterium Can Defeat Vancomycin Resistance
Author(s) -
Herold Kerstin,
Gollmick Friedrich A.,
Groth Ingrid,
Roth Martin,
Menzel KlausDieter,
Möllmann Ute,
Gräfe Udo,
Hertweck Christian
Publication year - 2005
Publication title -
chemistry – a european journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.687
H-Index - 242
eISSN - 1521-3765
pISSN - 0947-6539
DOI - 10.1002/chem.200500320
Subject(s) - polyketide , stereochemistry , glycoside , substituent , strain (injury) , streptomyces , chemistry , bacteria , biology , microbiology and biotechnology , biochemistry , gene , genetics , biosynthesis , anatomy
Cervimycins A–D are novel polyketide glycosides with significant activity against multi‐drug‐resistant staphylococci and vancomycin‐resistant enterococci. They are produced by a strain of Streptomyces tendae , isolated from an ancient cave. The structures of the cervimycins were determined by performing extensive NMR and chemical degradation studies. All cervimycins have a common tetracyclic polyketide core that is substituted with unusual di‐ and tetrasaccharide chains, composed exclusively of trideoxysugars; however, they differ in the acetyl and carbamoyl ring substituent and in the highly unusual terminal methylmalonyl and dimethylmalonyl residues.